Allogene Therapeutics, Inc. Annual Return On Equity in % from 2018 to 2023

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
Allogene Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from 2018 to 2023.
  • Allogene Therapeutics, Inc. Return On Equity for the quarter ending September 30, 2024 was -58.1 %, a 5.47% decline year-over-year.
  • Allogene Therapeutics, Inc. annual Return On Equity for 2023 was -56.8 %, a 28.5% decline from 2022.
  • Allogene Therapeutics, Inc. annual Return On Equity for 2022 was -44.2 %, a 142% decline from 2021.
  • Allogene Therapeutics, Inc. annual Return On Equity for 2021 was -18.3 %, a 43.7% increase from 2020.
Return On Equity, Annual (%)
Return On Equity, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2023 -56.8 -12.6 -28.5% Jan 1, 2023 Dec 31, 2023
2022 -44.2 -25.9 -142% Jan 1, 2022 Dec 31, 2022
2021 -18.3 +14.2 +43.7% Jan 1, 2021 Dec 31, 2021
2020 -32.4 -3.87 -13.6% Jan 1, 2020 Dec 31, 2020
2019 -28.6 +182 +86.4% Jan 1, 2019 Dec 31, 2019
2018 -210 Jan 1, 2018 Dec 31, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.